Polygenic risk scores: predicting disease risk from DNA
Polygenic risk scores combine thousands of genetic variants to predict disease risk. Learn how PRS works, what it reveals about longevity, and its current limitations.
Most diseases are not caused by a single gene. Heart disease, diabetes, Alzheimer’s, and cancer each involve hundreds or thousands of genetic variants, each contributing a tiny fraction of risk. For decades, this complexity made genetic disease prediction impractical. That changed with polygenic risk scores (PRS).
A PRS combines the effects of thousands — sometimes millions — of genetic variants into a single number that estimates your genetic predisposition for a specific condition. A 2024 study in Scientific Reports used PRS to predict human longevity, finding that individuals in the highest decile of composite longevity scores lived up to 4.8 years longer than those in the lowest.
This technology is moving rapidly from research into clinical practice. But it comes with important caveats — and understanding both the power and the limitations of PRS is essential before acting on the results.
What you’ll learn:
- How polygenic risk scores work and what they measure
- Current clinical applications for longevity-relevant diseases
- The critical limitations every consumer should understand
- How PRS complements biological age tracking
What are polygenic risk scores?
A polygenic risk score is a statistical estimate of an individual’s genetic predisposition to a trait or disease, calculated by summing the effects of many genetic variants (typically single nucleotide polymorphisms, or SNPs) identified through genome-wide association studies (GWAS).
Quick definition: A polygenic risk score (PRS) combines thousands of genetic variants into a single number representing your genetic risk for a specific disease or trait. Higher scores indicate greater genetic predisposition — but not certainty.
How PRS is calculated
- GWAS identifies variants — large studies (100,000+ participants) find SNPs associated with a trait
- Effect sizes are estimated — each variant’s contribution to risk is quantified
- Scores are summed — your personal genotype at each variant is multiplied by its effect size and summed
- Population comparison — your total score is compared to a reference population
PRS vs single-gene tests
| Feature | Single-gene test | Polygenic risk score |
|---|---|---|
| Variants tested | 1–few | Thousands to millions |
| Risk per variant | High (often >10x) | Very small (1.01–1.05x each) |
| Diseases covered | Rare genetic conditions | Common complex diseases |
| Predictive power | High for specific conditions | Moderate for populations |
| Examples | BRCA1/2, Huntington’s, ApoE4 | Heart disease, diabetes, cancer risk |
PRS and longevity
Polygenic longevity scores
Researchers have developed multiple polygenic longevity scores (PLS) that predict lifespan:
- 11 different PLS have been validated in the UK Biobank, predicting both longer life and resilience to age-related conditions
- Individuals with the highest PLS lived 0.31 to 1.98 years longer on average
- The most predictive PLS prioritize variants involved in lipid metabolism, BMI, and cognitive performance
- A composite PRS achieved a 4.8-year lifespan difference between highest and lowest deciles
Disease-specific PRS relevant to aging
| Disease | PRS predictive value | Longevity relevance |
|---|---|---|
| Coronary artery disease | High — identifies top 8% at 3x risk | Leading cause of death |
| Type 2 diabetes | Moderate-high | Metabolic aging accelerator |
| Alzheimer’s disease | Moderate (ApoE4 dominates) | Cognitive healthspan |
| Breast/prostate cancer | Moderate | Age-related disease burden |
| Atrial fibrillation | Moderate | Cardiovascular aging |
| Osteoporosis | Moderate | Musculoskeletal aging |
The interaction between genetics and lifestyle
A landmark study found that genetic predisposition to longer lifespan interacts with lifestyle factors in predicting mortality. Crucially, favorable lifestyle largely compensated for high genetic risk — people with high genetic risk but healthy lifestyles had lower mortality than those with low genetic risk and unhealthy lifestyles.
This finding fundamentally shapes how PRS should be interpreted: your genetic score tells you where to focus your effort, not what your outcome will be.
Current clinical applications
What PRS can do now
- Risk stratification — identify individuals who would benefit most from early screening
- Preventive targeting — guide statin decisions, mammography timing, diabetes prevention programs
- Treatment selection — some PRS predict treatment response
- Motivation — knowing elevated genetic risk increases adherence to preventive behaviors
What PRS cannot do yet
- Diagnose disease — PRS estimates risk, not presence
- Replace clinical assessment — family history, blood tests, and imaging remain essential
- Predict individual outcomes — PRS works for populations, not individuals
- Apply equally across ancestries — most GWAS are conducted in European populations, limiting accuracy for others
4 key limitations to understand
1. Ancestry bias
Most GWAS data comes from populations of European descent. PRS accuracy decreases significantly for individuals of African, Asian, and Indigenous ancestry. This is an active area of research, but current scores should be interpreted cautiously for non-European populations.
2. Environmental interaction
PRS captures genetic predisposition in a vacuum — it does not account for diet, exercise, stress, sleep, or environmental exposures. The field of nutrigenomics addresses this gap — showing how specific gene-diet interactions (such as MTHFR affecting folate metabolism) can be directly countered with targeted nutrition. Two people with identical PRS can have vastly different outcomes based on lifestyle.
3. Missing heritability
Current PRS typically explain only 5–20% of the heritability of complex diseases. The remaining heritability involves rare variants, gene-gene interactions, and epigenetic factors not captured by standard GWAS.
4. Psychological impact
Learning about elevated genetic risk can cause anxiety, fatalism, or genetic determinism — the belief that genes are destiny. Genetic counseling is essential to contextualize results within the broader picture of modifiable risk factors.
How PRS complements biological age
PRS and biological age measure fundamentally different things:
| Measure | What it captures | Modifiable? | Time frame |
|---|---|---|---|
| PRS | Genetic predisposition (fixed at birth) | No | Lifetime risk |
| Biological age | Current physiological state | Yes | Real-time snapshot |
| Pace of aging | Rate of biological aging | Yes | Ongoing trend |
| Epigenetic clocks | DNA methylation state | Partially | Current state |
The most powerful approach combines all four: PRS identifies your genetic vulnerabilities, biological age shows how your body is currently performing, pace of aging reveals your trajectory, and epigenetic clocks measure the molecular state. Understanding how Horvath, GrimAge, and DunedinPACE each measure different aspects of aging helps you choose the right clock for interpreting whether your genetic risk is being expressed or suppressed.
How SuperAge helps you act on genetic risk
Your PRS is fixed — your biological age is not. SuperAge bridges the gap between knowing your genetic risk and doing something about it.
Biological age as the actionable counterpart
While PRS tells you what diseases you are genetically predisposed to, SuperAge’s biological age tells you whether your lifestyle is counteracting or compounding that predisposition. A biological age below your chronological age — regardless of your PRS — means your interventions are working.
Lifestyle tracking that targets genetic risk
SuperAge monitors the behaviors most relevant to longevity: exercise consistency, deep sleep, HRV, and stress recovery. These are precisely the modifiable factors that research shows can partially override genetic risk.
Frequently asked questions
Should I get a polygenic risk score test?
PRS testing is most valuable if you want to understand your genetic predisposition to common diseases and are prepared to act on the information. Direct-to-consumer services (23andMe, Nebula Genomics) provide some PRS data. Clinical PRS is increasingly available through healthcare providers. Always pair results with genetic counseling.
Can lifestyle really override high genetic risk?
Yes — to a significant extent. Research consistently shows that favorable lifestyle factors (exercise, diet, sleep, not smoking) reduce disease risk by 30–50% even in those with the highest genetic risk scores. PRS identifies where your efforts matter most, but it does not determine your outcome.
How is PRS different from testing for BRCA or ApoE?
BRCA and ApoE are single-gene tests that identify high-impact rare (BRCA) or common (ApoE) variants with large individual effects. PRS aggregates many variants with tiny individual effects. Both approaches are complementary — single-gene tests for high-penetrance variants, PRS for common complex diseases.
Key takeaways
- PRS combines thousands of genetic variants into a single disease risk score
- Longevity PRS predicts up to 4.8 years lifespan difference between highest and lowest deciles
- Lifestyle largely compensates for high genetic risk — PRS tells you where to focus, not what will happen
- Ancestry bias is a major limitation — current scores are most accurate for European-descent populations
- PRS and biological age are complementary — genetics reveals predisposition, biological age reveals current reality
Know your risk, then change your trajectory
Your DNA is the hand you were dealt. Your biological age is how you are playing it. The science is clear: lifestyle interventions can substantially overcome genetic predisposition — but only if you know where to focus and track whether your strategy is working.
Ready to measure what you can change? Download SuperAge and start tracking the biological age, HRV, sleep, and exercise markers that reveal whether your lifestyle is overriding — or reinforcing — your genetic risk.
References
- Timmers PR et al. — “Polygenic prediction of human longevity on the supposition of pervasive pleiotropy” — Scientific Reports (2024)
- Jiang L et al. — “The relationship between 11 different polygenic longevity scores, parental lifespan, and disease diagnosis” — GeroScience (2024)
- Khera AV et al. — “Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations” — Nature Genetics (2018)
- Lewis CM and Vassos E — “Polygenic risk scores: from research tools to clinical instruments” — Genome Medicine (2020)
- Lourida I et al. — “Association of lifestyle and genetic risk with incidence of dementia” — JAMA (2019)
- Martin AR et al. — “Clinical use of current polygenic risk scores may exacerbate health disparities” — Nature Genetics (2019)
Last updated: 2026-03-23. This article is regularly reviewed to ensure accuracy.
Related Articles
MTHFR mutations: methylation, homocysteine, and biological age
MTHFR gene variants affect methylation, raise homocysteine, and may accelerate biological aging. Learn what the science says and how to optimize your methylation cycle.
